Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Public ClinicalTrials.gov record NCT03761914. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
Study identification
- NCT ID
- NCT03761914
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 26 participants
Conditions and interventions
Conditions
Interventions
- galinpepimut-S Biological
- pembrolizumab Biological
- Montanide Other
- GM-CSF Biological
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2019
- Primary completion
- Jul 4, 2022
- Completion
- Oct 26, 2022
- Last update posted
- Nov 18, 2024
2019 – 2022
United States locations
- U.S. sites
- 12
- U.S. states
- 6
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Joseph Heritage Healthcare | Santa Rosa | California | 95403 | — |
| Innovative Clinical Research Institute (ICRI) | Whittier | California | 90603 | — |
| Miami Cancer Institute at Baptist Health, Inc. | Miami | Florida | 33176 | — |
| Memorial Sloan Kettering Cancer Center | Basking Ridge | New Jersey | 07920 | — |
| Memorial Sloan Kettering Cancer Center | Middletown | New Jersey | 07748 | — |
| Memorial Sloan Kettering Cancer Center | Montvale | New Jersey | 07645 | — |
| Memorial Sloan Kettering Cancer Center | Commack | New York | 11725 | — |
| Memorial Sloan Kettering Cancer Center | Harrison | New York | 10604 | — |
| Memorial Sloan Kettering Cancer Center | Nassau | New York | 11553 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| MD Anderson Cancer Center | Houston | Texas | 77054 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03761914, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2024 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03761914 live on ClinicalTrials.gov.